Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 1
1954 4
1957 1
1958 2
1959 3
1960 2
1961 2
1962 3
1963 5
1964 13
1965 7
1966 12
1967 7
1968 10
1969 8
1970 11
1971 22
1972 15
1973 12
1974 19
1975 20
1976 18
1977 20
1978 34
1979 23
1980 28
1981 22
1982 19
1983 22
1984 16
1985 13
1986 23
1987 17
1988 23
1989 23
1990 24
1991 24
1992 11
1993 9
1994 7
1995 20
1996 16
1997 22
1998 14
1999 9
2000 19
2001 32
2002 28
2003 8
2004 22
2005 18
2006 16
2007 16
2008 18
2009 9
2010 14
2011 10
2012 16
2013 10
2014 10
2015 18
2016 15
2017 14
2018 20
2019 14
2020 25
2021 34
2022 30
2023 27
2024 16
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,090 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Janjigian YY, et al. Among authors: kozlov v. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701. Epub 2025 Jun 1. N Engl J Med. 2025. PMID: 40454643 Clinical Trial.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. Among authors: kozlov v. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. Among authors: kozlov v. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, Chouaid C, Dechev H, Dowlati A, Fernández Núñez N, Ivashchuk O, Kiladze I, Kortua T, Leighl N, Luft A, Makharadze T, Min Y, Quantin X; DISTINCT study investigators. Edelman MJ, et al. Among authors: kozlov v. Lung Cancer. 2022 Apr;166:135-142. doi: 10.1016/j.lungcan.2022.03.003. Epub 2022 Mar 4. Lung Cancer. 2022. PMID: 35278766 Clinical Trial.
Victor Kozlov's reply.
Kozlov V. Kozlov V. Opt Express. 2002 Feb 11;10(3):157-8. doi: 10.1364/oe.10.000157. Opt Express. 2002. PMID: 19424344 Free article.
[Burso-omentoscopy].
Kozlov VA, Cherniad'ev SA. Kozlov VA, et al. Khirurgiia (Mosk). 1989 Feb;(2):109-10. Khirurgiia (Mosk). 1989. PMID: 2523497 Russian. No abstract available.
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
Laktionov K, Smolin A, Stroyakovskiy D, Moiseenko V, Dvorkin M, Andabekov T, Cheng Y, Liu B, Kozlov V, Odintsova S, Dvoretsky S, Mochalova A, Urda M, Yi T, Li X, László U, Müller V, Bogos K, Fadeeva N, Musaev G, Liu Q, Kirtbaya D, Shi J, Gladkov O, Narimanov M, Semiglazova T, Khasanova A, Chovanec J, Andrašina I, Szabová A, Rosinská O, Sudekova D, Zsolt PS, Ran F, Sun M, Jiang O, Chen R, Zhao E, Liu C, Tan W, Pirmagomedov A, Poddubskaya E, Kislov N, Shumskaya I, Sorokina I, Zinkina-Orikhan A, Linkova Y, Fogt S, Liaptseva D, Siliutina A, Basova O, Kryukov F. Laktionov K, et al. Among authors: kozlov v. Eur J Cancer. 2025 Feb 25;217:115255. doi: 10.1016/j.ejca.2025.115255. Epub 2025 Jan 21. Eur J Cancer. 2025. PMID: 39879779 Clinical Trial.
New Insight into the Role of AhR in Lung Carcinogenesis.
Akhmetova DA, Kozlov VV, Gulyaeva LF. Akhmetova DA, et al. Among authors: kozlov vv. Biochemistry (Mosc). 2022 Nov;87(11):1219-1225. doi: 10.1134/S0006297922110013. Biochemistry (Mosc). 2022. PMID: 36509717 Free article. Review.
Spin Noise of a Halide Perovskite.
Kozlov VO, Selivanov NI, Stoumpos CC, Kozlov GG, Zapasskii VS, Kapitonov YV, Smirnov DS, Ryzhov II. Kozlov VO, et al. Phys Rev Lett. 2025 Jun 27;134(25):256901. doi: 10.1103/6p4z-shzt. Phys Rev Lett. 2025. PMID: 40743028
1,090 results